Zoetis hikes dividend under shareholder pressure; Investors sue Valeant, Ackman for insider trading;

@FiercePharma: Have you read our latest report? Not to be missed: The top 10 patent losses of 2015. Report | Follow @FiercePharma

@CarlyHFierce: ICYME: Flush-with-cash Shire revisits deal for NPS Pharma. More | Follow @CarlyHFierce

> Animal health leader Zoetis ($ZTS), under pressure to improve shareholder value since activist investor Bill Ackman bought up a $1.5 billion stake, says its first-quarter 2015 dividend will be 8.3 cents per share--15% higher than this year's dividend rate. Story

> Investors who sold shares of Allergan ($AGN) between February and April are suing Bill Ackman and Valeant ($VRX) for insider trading. More

> The FDA has cleared Teva's ($TEVA) allergy drug QNASL in children age 4 to 11. Release

> Sanofi ($SNY) has leased 40,000 square feet of office space in Miami, FL. Report

> The EU has recommended approval of Italian drugmaker Chiesi's rare eye disease drug Holoclar, the first medicine containing stem cells. Story

> Novartis ($NVS) had won approval in India to import and market its Cushing's disease drug Pasireotide without having to do local clinical trials. Story

Medical Device News

@FierceMedDev: ICYMI yesterday: FDA warns against inappropriate use of fetal ultrasound imaging and heartbeat monitoring. Article | Follow @FierceMedDev

@EmilyWFierce: Myriad Genetics stymied in BRCA breast cancer test patent battle. Story | Follow @EmilyWFierce

> Private equity firm backs Sonoma Orthopedic with $12M to get ankle implant to market. More

> Small cap Cerus spikes on back-to-back Intercept approvals by FDA. News

> FDA outlines UDI implementation plans for 2015. More

Biotech News

@FierceBiotech: Juno banks $265M in an IPO, pushing the next big thing in oncology. Story | Follow @FierceBiotech

@JohnCFierce: You want to start an argument? Walk into a room full of neuroscientists and shout 'amyloid beta.' | Follow @JohnCFierce

@DamianFierce: $MRK + $CBST tick-tock shows Frazier wanted $HSP decision contingency and Bonney talked him out of it. More | Follow @DamianFierce

> Gilead buys into Ono's cancer drug as it scales up in oncology. News

> Lilly makes amends with Adocia in $570M diabetes deal. Story

> Roche scuttles PhIII Alzheimer's study in yet another setback for the field. More

And Finally... According to a new investigation, hundreds of thousands of Americans are falling prey to pharma spam and buying drugs from rogue pharmacy websites. Report

Suggested Articles

Without any new data, Sarepta appealed an FDA rejection and got a surprising nod for Vyondys 53—its second med approved on a surrogate marker.

Roche’s Tecentriq and Cotellic pairing went 0 for 1 in phase 3 melanoma trials—but Friday, they reversed that trend in a Zelboraf combo test.

Stephen Hahn, an oncologist who served as the chief medical officer for the MD Anderson Cancer Center, has secured Senate confirmation as FDA head.